Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

Nature Medicine volume 3, pages 625–631 (1997)Cite this article

Abstract

Daily treatment of mice with recombinant human Flt3 ligand (huFlt3L) results in a dramatic numerical increase in the number of dendritic cells (DCs) in vivo. Since DCs are pivotal in the induction of immune responses, we tested whether Flt3L treatment of mice challenged with a syngeneic methylcholanthrene (MCA)-induced fibrosarcoma would augment the generation of effective antitumor immune responses in vivo. Flt3L treatment not only induced complete tumor regression in a significant proportion of mice, but also decreased tumor growth rate in the remaining mice. A preliminary characterization of the cellular mechanisms involved suggests that Flt3L may be important in the treatment of cancer in situ through the generation of specific antitumor immune responses.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pardoll, D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399–415 (1995).

    Article  CAS  Google Scholar 

  2. Liu, B., Podack, E.R., Allison, J.P. & Malek, T.R. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J. Immunol. 156, 1117–1125 (1996).

    CAS  PubMed  Google Scholar 

  3. Metlay, J.P. et al. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J.exp Med. 171, 1753–1771 (1990).

    Article  CAS  Google Scholar 

  4. Kraal, G., Breel, M., Janse, M. & Bruin, G. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J. Exp.Med Annu. 163, 981–997 (1986).

    Article  CAS  Google Scholar 

  5. Jiang, W. et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375, 151–155 (1995).

    Article  CAS  Google Scholar 

  6. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. rev. Immunol. 9, 271–296 (1991).

    Article  CAS  Google Scholar 

  7. Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297–1302 (1995).

    Article  CAS  Google Scholar 

  8. Thomson, A.W. et al. Microchimerism, dendritic cell progenitors and transplantation tolerance. Steem Cells. 13, 622–639 (1995).

    Article  CAS  Google Scholar 

  9. Young, J.W. & Inaba, K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183, 7–11 (1996).

    Article  CAS  Google Scholar 

  10. Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1 -associated cytokines. J. Exp. Med. 183, 87–97 (1996).

    Article  CAS  Google Scholar 

  11. Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T. & Falo, L.D. Jr. Peptidepulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283–287 (1996).

    Article  CAS  Google Scholar 

  12. Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317–322 (1996).

    Article  CAS  Google Scholar 

  13. Mckenna, H.J. & Lyman, S.D. Biology of Flt3 ligand, a novel regulator of hematopoietic stem and progenitor cells. in Bone Marrow Transplantation: Basic and Clinical Studies (eds. Ikehara, S., Takaku, F. & Good, R.A.) 85–93 (Springer, New York 1996).

    Chapter  Google Scholar 

  14. Lyman, S.D. Biology of Flt3 ligand and receptor. Int. J. Hematol. 62, 63–73 (1996).

    Article  Google Scholar 

  15. Maraskovsky, E. et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953–1962 (1996).

    Article  CAS  Google Scholar 

  16. Brasel, K. et al. Hematological effects of Flt3 ligandin vivoin mice. Blood 88, 2004–2012 (1966).

    Google Scholar 

  17. Brent, L. & Medawar, P.B. Quantitative studies on tissue transplantation immunity. VIII. The effect of radiation. Proc. R. Soc. London (Biol.) 165, 413 (1996).

    Google Scholar 

  18. Lynch, D.H. & Miller, R.E. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice. Eur. J. Immunol 21, 1403–1410 (1991).

    Article  CAS  Google Scholar 

  19. Brasel, K. et al. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia 9, 1212–1218 (1995).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department oflmmunobiology, Immunex Corporation, 51 University Street, Seattle, Washington, 98101, USA

    David H. Lynch, Alice Andreasen, Eugene Maraskovsky & Robert E. Miller

  2. Department of Biometrics and Immunex Corporation, 51 University Street, Seattle, Washington, 98101, USA

    James Whitmore

  3. Department of Molecular Immunology, Immunex Corporation, 51 University Street, Seattle, Washington, 98101, USA

    Joann C.L. Schuh

Authors
  1. David H. Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alice Andreasen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugene Maraskovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Whitmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert E. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joann C.L. Schuh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lynch, D., Andreasen, A., Maraskovsky, E. et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3, 625–631 (1997). https://doi.org/10.1038/nm0697-625

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0697-625

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing